LY-503,430
 | |
| IUPAC ime | |
|---|---|
4'- {(1S)-1-fluoro-2-[(izopropilsulfonil)amino]-1-metiletil} -N-metilbifenil-4-karboksamid | |
| Klinički podaci | |
| Način primene | oralno |
| Pravni status | |
| Pravni status |
|
| Identifikatori | |
| CAS broj | 625820-83-9  |
| ATC kod | none |
| Sinonimi | LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide |
| Hemijski podaci | |
| Formula | C20H25FN2O3S |
| Molarna masa | 392,49 g/mol |
| |
LY-503,430 je ampakinski lek koji je razvila kompanija Eli Lili.[1]
LY-503,430 proizvodi nootropne i neuroprotektivne efekte, čime redukuje moždana oštećenja uzrokovana 6-hidroksidopaminom ili MPTP-om. On isto tako povišava nivoe neurotrofnog faktora BDNF u mozgu, posebno u substantia nigra, hipokampusu i striatumu.[2][3] On je oralno aktivan. LY-503,430 se razvija za moguću primenu u lečenju Parkinsonove bolesti. Moguće je će naći primenu i u tretmanju Alchajmerove bolesti, depresije i šizofrenije.[4][5]
Reference
[уреди | уреди извор]- ^ O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). „LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease”. CNS Drug Reviews. 11 (1): 77—96. PMID 15867954. doi:10.1111/j.1527-3458.2005.tb00037.x.
|first2=захтева|last2=у Authors list (помоћ);|first3=захтева|last3=у Authors list (помоћ);|first4=захтева|last4=у Authors list (помоћ);|first5=захтева|last5=у Authors list (помоћ);|first6=захтева|last6=у Authors list (помоћ) - ^ Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P; et al. (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 752—62. PMID 12730350. doi:10.1124/jpet.103.049445.
- ^ Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 293—8. PMID 16803862. doi:10.1124/jpet.106.105734.
- ^ O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders. 3 (3): 181—94. PMID 15180479. doi:10.2174/1568007043337508.
|first2=захтева|last2=у Authors list (помоћ);|first3=захтева|last3=у Authors list (помоћ);|first4=захтева|last4=у Authors list (помоћ) - ^ O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets. 8 (5): 603—20. PMID 17504104. doi:10.2174/138945007780618517.
|first2=захтева|last2=у Authors list (помоћ)
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
